Logo Logo
Switch Language to German

Radon, Katja ORCID logoORCID: https://orcid.org/0000-0002-5271-3972; Bakuli, Abhishek; Puetz, Peter; Le Gleut, Ronan; Guggenbuehl Noller, Jessica Michelle; Olbrich, Laura; Saathoff, Elmar; Gari, Merce; Schaelte, Yannik; Frahnow, Turid; Woelfel, Roman; Pritsch, Michael; Rothe, Camilla; Pletschette, Michel; Rubio-Acero, Raquel; Beyerl, Jessica; Metaxa, Dafni; Forster, Felix ORCID logoORCID: https://orcid.org/0000-0002-3670-9244; Thiel, Verena; Castelletti, Noemi; Riess, Friedrich; Diefenbach, Maximilian N.; Fröschl, Günter ORCID logoORCID: https://orcid.org/0000-0003-2743-7555; Bruger, Jan; Winter, Simon; Frese, Jonathan; Puchinger, Kerstin; Brand, Isabel; Kroidl, Inge; Wieser, Andreas; Hoelscher, Michael; Hasenauer, Jan and Fuchs, Christiane (2021): From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany). In: Springer Nature Infectious Diseases, Vol. 21, No. 1, 925

Full text not available from 'Open Access LMU'.


Background In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. Methods The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot;DBS). Blood was analysed using the Elecsys (R) Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. Results Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. Conclusion The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.

Actions (login required)

View Item View Item